Terminology Service for NFDI4Health
JSON

Lapatinib Ditosylate

Go to external page http://purl.obolibrary.org/obo/NCIT_C66878

The ditosylate salt of lapatinib, a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. [ ]

Term info

Label

Lapatinib Ditosylate

Synonyms
  • 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl), bis(4-methylbenzenesulfonate), Monohydrate
  • LAPATINIB DITOSYLATE
  • Lapatinib Ditosylate
  • Tykerb
  • lapatinib ditosylate
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C63923, NCIT_C116977, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib ditosylate is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.

Accepted Therapeutic Use For

HER2 positive metastatic breast cancer

CAS Registry

388082-78-8

Chemical Formula

C29H26ClFN4O4S.2C7H8O3S.H2O

Display Name

Lapatinib Ditosylate

FDA UNII Code

G873GX646R

Has Free Acid Or Base Form

http://purl.obolibrary.org/obo/NCIT_C26653

Has Target

http://purl.obolibrary.org/obo/NCIT_C17068, http://purl.obolibrary.org/obo/NCIT_C17319, http://purl.obolibrary.org/obo/NCIT_C41625

Legacy Concept Name

Lapatinib_Ditosylate

Preferred Name

Lapatinib Ditosylate

Semantic Type

Pharmacologic Substance

UMLS CUI

C1504917

code

C66878